For Emergency Use Authorization Only | For in vitro diagnostic use | Rx Only

Product Overview

The RapCov™ Rapid COVID-19 Test is a lateral flow immunoassay intended for the qualitative detection of IgG antibodies to the SARS-CoV-2 virus in human fingerstick whole blood samples. The Test is intended for use to identify individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.

Testing of fingerstick whole blood specimens is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a that meet the requirements to perform high, moderate, or waived complexity tests. Testing of fingerstick whole blood specimens is also authorized for use at the Point of Care (POC), i.e., inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.

Products Benefits

• Highly accurate: 93% overall test sensitivity and 100% test specificity
• Fast: Results in 15 minutes at the Point-of-Care (PoC)
• No shipment delay: Manufactured in the USA and stocked locally

Related Information

* Check out the Instructions for Use and Quick Reference Instructions for more details about this product.

* Read the Flyer for our product highlights.

* Read the NCI/NIH Evaluation Report for our data and results.

* Download our Letters of Authorization (Original, Revised)  from FDA.

* Download our healthcare provider fact sheet and patient fact sheet.

Contact Us

* Request a quote and your BGI representative will reply to you within 24 hours.

In the United States:
– This test has not been FDA cleared or approved but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories.
– This test has been authorized only for detecting the presence of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens.
– The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro
diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb3(b)(1), unless the
declaration is terminated, or authorization is revoked sooner